Night-Shift Work Duration and Risk of Colorectal Cancer According to IRS1 and IRS2 Expression
-
2020/01/01
-
Details
-
Personal Author:Chan AT ; Fuchs CS ; Giannakis M ; Giovannucci E ; Gu M ; Hamada T ; Kim SA ; Kosumi K ; Liu L ; Ma Y ; Meyerhardt JA ; Morikawa T ; Nevo D ; Nishihara R ; Nowak JA ; Ogino S ; Papantoniou K ; Schernhammer ES ; Shi Y ; Song M ; Sui J ; Wang M ; Wu K ; Zhang X
-
Description:Background: We hypothesized that the risk of colorectal cancer in night-shift workers might be different according to insulin receptor substrate status. Methods: Among 77,470 eligible women having night work assessed in the Nurses' Health Study, we documented a total of 1,397 colorectal cancer cases, of which 304 or 308 had available data on IRS1 and IRS2, respectively. We used duplication-method Cox proportional hazards regression analysis for competing risks to calculate HRs and 95% confidence intervals (CI) for each colorectal cancer subtype. We measured tumor IRS1 or IRS2 expression by immunohistochemistry (IHC). Results: Compared with women who never worked night shifts, those working >/=15 years night shifts had a marginal trend of increased overall risk of colorectal cancer (Ptrend = 0.06; multivariable HR = 1.20; 95% CI, 0.99-1.45). Longer duration of night-shift work was associated with a higher risk of IRS2-positive tumors (multivariable HR = 2.69; 95% CI, 1.48-4.89; Ptrend = 0.001, >/=15 years night shifts vs. never) but not with IRS2-negative tumors (multivariable HR = 0.90; 95% CI, 0.54-1.51; Ptrend = 0.72; Pheterogeneity for IRS2 = 0.008). Similarly, the corresponding multivariable HRs were 1.81 for IRS1-positive tumors (95% CI, 0.94-3.48; Ptrend = 0.06) and 1.13 for IRS1-negative tumors (95% CI, 0.71-1.80; Ptrend = 0.56; Pheterogeneity for IRS1 = 0.02). Conclusions: Our molecular pathologic epidemiology data suggest a potential role of IRS in mediating carcinogenesis induced by night-shift work. Impact: Although these findings need validation, rotating night shift might increase colorectal cancer risk in women with abnormal insulin receptor pathways. [Description provided by NIOSH]
-
Subjects:
-
Keywords:
-
ISSN:1055-9965
-
Document Type:
-
Funding:
-
Genre:
-
Place as Subject:
-
CIO:
-
Topic:
-
Location:
-
Pages in Document:133-140
-
Volume:29
-
Issue:1
-
NIOSHTIC Number:nn:20059254
-
Citation:Cancer Epidemiol Biomark Prev 2020 Jan; 29(1):133-140
-
Contact Point Address:Xuehong Zhang, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA 02115
-
Email:xuehong.zhang@channing.harvard.edu
-
Federal Fiscal Year:2020
-
Performing Organization:Brigham and Women's Hospital, Inc., Boston, Massachusetts
-
Peer Reviewed:True
-
Start Date:20100801
-
Source Full Name:Cancer Epidemiology, Biomarkers & Prevention
-
End Date:20190831
-
Collection(s):
-
Main Document Checksum:urn:sha-512:2726aa0eebcd1ffdfca9ade1a06ef7f0eeea4aba8cba453ad6d0c4dd7a8e967931f9d8592631153a7190f60688b45b7ab769c7ded5a8ec7509193a01ea8bbd14
-
Download URL:
-
File Type:
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like